LONE TREE, CO — Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, today announces FDA clearance of the new source=prnewswire%26utm medium=pressrelease%26utm campaign=cna-usbc or6 pat\ /1/0100019f5c50491b-5ee34679-e739-48a0-953a-e61d2dbcd670-000000/YhmiNjDJq3ubOeNA28kZrKef1bQ=473">Cochlear<sup>®</sup> Osia<sup>®</sup> 3 Sound Processor , the newest advancement of the 2yae...
Continue reading at Hearing Tracker
✦ The floor
Discussion
Signed responses from readers of the wire.
Clinicians fitting Osia system patients should note the availability of a rechargeable processor option, but await independent clinical performance data before drawing efficacy conclusions.
FDA clearance of a rechargeable bone-anchored sound processor expands options for patients who are candidates for osseointegrated (bone-anchored) hearing solutions.
- 01Cochlear's Osia 3 sound processor received FDA clearance, making it available in the U.S.
- 02The Osia 3 is rechargeable, replacing the need for disposable batteries.
- 03It is designed for use with Cochlear's existing osseointegrated (bone-anchored) implant system.
- 04No independent clinical efficacy or outcome data were presented in the announcement.
- 05Rechargeable form factor may improve convenience and long-term cost for patients.
The Osia 3 sound processor has received FDA clearance.
press releasesupportedThe Osia 3 is a rechargeable sound processor for Cochlear's bone-anchored implant system.
press releasesupported